

FOR IMMEDIATE RELEASE

For more information:

ImmunoQure AG
Dr. Edward Stuart
Chairman of the Board of Directors

+49 (0)171 4091427
edward.stuart@immunoqure.com

Sardinian patient support group establish a non-profit organization – APECED Sardegna for the support of APS-1/APECED patients

Düsseldorf, Germany September 29, 2017. ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today welcomed the establishment of a non-profit charity for APS-1/APECED patients who live in Sardinia.

APS-1/APECED is a monogenetic disorder whereby null or hypomorphic mutations in the AIRE gene greatly impair central T cell tolerance. Consequently, APS-1 patients are unable to optimally delete self-reactive T cells, leading to an accumulation of T cells and B cells that target a wide range of self-proteins. Consequently, APS-1/APECED patients suffer from a multitude of clinical conditions including but not limited to chronic mucocutaneous candidiasis, polyendocrinopathy and Addisons disease.

ImmunoQure's Chairman of the Board noted: "we welcome the establishment of APECED Sardegna and are confident that it will prove to be a helpful resource for APS-1/APECED patients in Sardinia. ImmunoQure was delighted to be asked to help in its establishment and look forward to positively contributing to its development in the coming years in a manner similar to how we have worked with the corresponding charity that supports Finnish APS-1/APECED patients – APECED Ry".

About ImmunoQure AG

ImmunoQure is a biotechnology company based in Düsseldorf, Germany that is focused on the research and development of patient-derived autoantibodies for the treatment of multiple diseases. Together with its partner Servier Laboratoires (Paris, France) its most advanced product is an anti-Type I interferon antibody. ImmunoQure was founded by a consortium of leading researchers from the Universities of Tartu, Estonia and Helsinki Finland, King's College, London UK, the APS-1/APECED patient support charity APECED Ry. ImmunoQure is financed by QureInvest II (SCS) SICAR, a specialist European life sciences entrepreneurial investment fund advised by HS LifeSciences GmbH, Düsseldorf, Germany.
